How Is Cancer Treatment in China? China’s Oncology System and Cross-Border Treatment Trends from an International Patient Perspective

By:DengYue International Business Division

For many years, when international patients thought about cancer treatment abroad, the first destinations that came to mind were usually the United States, Japan, Germany, or Singapore. In the field of oncology especially, traveling overseas for treatment was long regarded as one of the primary ways to access advanced medical resources.

However, in recent years, the global cancer treatment landscape has been undergoing significant changes. Increasing numbers of patients from Southeast Asia, the Middle East, Central Asia, Russian-speaking regions, and even parts of Europe and North America have started paying closer attention to China’s oncology system, while reassessing China’s capabilities in innovative therapies, solid tumor management, and international patient services.

This shift is not driven solely by treatment costs. More importantly, global oncology itself is entering a new era. Over the past several decades, cancer treatment mainly relied on surgery, chemotherapy, and radiotherapy. Today, with the rapid development of molecular medicine, immunology, and genomic testing technologies, oncology is moving toward precision and personalized medicine. More treatment strategies are now built around molecular tumor profiling, driver gene mutations, and the patient’s immune microenvironment. Emerging approaches such as targeted therapy, immunotherapy, CAR-T cell therapy, and ADCs (antibody-drug conjugates) are gradually reshaping the traditional logic of cancer treatment.

Against this backdrop, China’s oncology system has begun attracting increasing international attention. In the past, overseas perceptions of Chinese healthcare were often associated with basic medical services and generic drug manufacturing. However, with the rapid advancement of China’s innovative drug development, clinical research infrastructure, and specialized oncology capabilities, China is gradually becoming an important participant in global cancer innovation.

Particularly in areas such as lung cancer, liver cancer, breast cancer, gastrointestinal tumors, and certain complex solid tumors, China has made rapid progress in PD-1 immunotherapy, ADC drugs, bispecific antibodies, CAR-T therapy, and precision radiotherapy. As a result, more international patients are actively exploring Chinese oncology treatment resources.

Why Has China’s Oncology System Developed So Rapidly in Recent Years?

One of the key reasons behind the rapid growth of China’s oncology system is its extensive clinical resources. China has one of the world’s largest cancer patient populations, allowing major oncology centers to accumulate significant clinical experience within relatively short periods of time. Oncology itself is a discipline highly dependent on case accumulation, long-term follow-up, and combined treatment exploration.

This is especially true in cancers that are more prevalent in Asia, including lung cancer, liver cancer, gastric cancer, nasopharyngeal carcinoma, and gastrointestinal tumors, where Chinese physicians have accumulated substantial clinical experience through long-term practice.

For example, in liver cancer treatment, the relatively high prevalence of hepatitis B-related liver cancer in Asia has contributed to China developing mature clinical approaches in hepatobiliary and pancreatic tumor management, interventional oncology, and targeted therapy combined with immunotherapy. In lung cancer, because Asian patients have comparatively higher EGFR mutation rates, Chinese oncology centers have also built extensive experience in EGFR-targeted therapy, post-resistance treatment strategies, and combined immunotherapy approaches.

At the same time, China’s innovative pharmaceutical sector has entered a phase of rapid growth, significantly reshaping international perceptions of Chinese medicine. While many overseas patients still associate China’s pharmaceutical industry with generic drugs, the reality is that China has already produced a large number of innovative companies focusing on PD-1/PD-L1 immunotherapy, bispecific antibodies, ADCs, small-molecule targeted therapies, and CAR-T technologies.

Some Chinese-developed oncology drugs have already entered international markets, while an increasing number of multinational pharmaceutical companies are placing greater emphasis on China during global multi-center clinical trial development. For international patients, this means China may represent not only different treatment costs, but also access to emerging therapies, combination treatment strategies, and clinical research opportunities.

Innovative Therapies Are Reshaping Global Solid Tumor Management

Much of the international attention toward China’s oncology sector today is closely linked to the speed of development in innovative therapies.

Among them, immunotherapy has gradually become a major treatment direction across multiple cancer types. Compared with traditional chemotherapy, immunotherapy focuses more on activating the patient’s own immune system to recognize and attack tumor cells. China has already accumulated extensive experience in immunotherapy-related treatment for lung cancer, liver cancer, nasopharyngeal carcinoma, esophageal cancer, and several other tumor types. PD-1-related therapies, in particular, have become one of the most frequently discussed treatment areas among international patients.

At the same time, targeted therapy continues pushing oncology further toward precision medicine. With the wider adoption of genomic testing, more treatment decisions are now built around driver genes such as EGFR, ALK, ROS1, HER2, and KRAS. For some advanced-stage patients, molecular profiling directly affects treatment pathways, and the continued development of precision medicine has led increasing numbers of international patients to explore China’s genomic testing and targeted therapy resources.

Beyond immunotherapy and targeted therapy, ADCs (antibody-drug conjugates) have also become one of the hottest areas in global oncology. ADCs are often considered a combination of targeted therapy and chemotherapy. Their core mechanism involves using antibodies to precisely identify tumor cells before delivering cytotoxic drugs directly to them, thereby improving precision while reducing some systemic effects associated with conventional chemotherapy.

China’s ADC research activity is currently highly active in breast cancer, lung cancer, ovarian cancer, gastric cancer, and urothelial carcinoma, which is another important reason why more international patients are beginning to pay attention to China’s innovative oncology resources.

Why Are CAR-T and Cell Therapies Receiving So Much International Attention?

CAR-T is one of the most closely watched developments in modern oncology and essentially belongs to the field of cellular immunotherapy. Its core mechanism involves extracting the patient’s own immune cells, genetically engineering them, and reinfusing them into the body so they can recognize and attack cancer cells more effectively.

Currently, CAR-T therapy is mainly applied in hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, although research into solid tumor applications continues to expand. As a result, more international patients are actively searching for information such as “Where can CAR-T be performed in China?”, “How much does CAR-T treatment cost in China?”, and “Can international patients apply for CAR-T evaluation in China?”

China already has multiple approved CAR-T products, while many research centers are advancing next-generation CAR-T technologies and solid tumor-related studies. However, it is important to emphasize that CAR-T is not suitable for every patient. Treatment suitability still requires comprehensive evaluation by specialized oncology teams based on cancer type, disease stage, prior treatments, physical condition, and immune status.

For international patients, the growing interest in CAR-T is not only about the technology itself, but also about the rapid expansion of the global cell therapy industry, with China becoming an increasingly important participant in this field.

Why Is Guangzhou Emerging as an Important Oncology Destination for International Patients?

In addition to Beijing and Shanghai, Guangzhou has gradually become one of China’s most closely watched oncology cities among international patients. For patients from Southeast Asia, the Middle East, and countries connected through the Belt and Road Initiative, Guangzhou offers strong practical advantages in international transportation, medical resource concentration, and cross-border healthcare accessibility.

As one of the major medical hubs in southern China, Guangzhou not only possesses concentrated oncology resources, but was also among the earlier Chinese cities to begin developing international patient service systems. In recent years, as demand from overseas patients has increased, more medical institutions in Guangzhou have strengthened international patient centers, multilingual communication services, overseas remote consultations, and international insurance support, making cross-border oncology treatment increasingly systematic.

At the same time, Guangzhou has long maintained strong commercial and population exchanges with Southeast Asia, which has led many overseas patients to prioritize Guangzhou when exploring Chinese medical resources. For patients requiring long-term follow-up, staged treatment, or ongoing cross-border care management, transportation convenience and international patient coordination often become just as important as the treatment itself.

International Patients Are Paying More Attention to Specialized Solid Tumor Hospitals

In the past, many patients focused primarily on choosing the largest comprehensive hospitals. However, as oncology moves toward greater specialization and precision medicine, more international patients are beginning to pay attention to whether a hospital is genuinely focused on oncology itself, particularly whether it has comprehensive systems for managing complex solid tumors.

For many overseas patients, key concerns often include:

● Whether the hospital has MDT (multidisciplinary team) capabilities

● Whether it has long-term experience managing solid tumors

● Whether it supports international patient communication

● Whether remote medical record evaluation is available

● Whether it provides cross-border treatment coordination

Within this trend, oncology institutions specializing in solid tumors and developing international patient service systems are gradually gaining international visibility.

One example is Royalalee Cancer Hospital in Guangzhou, which has been strengthening both its solid tumor specialization and international patient service capabilities in recent years. Unlike traditional large general hospitals, Royalalee places greater emphasis on oncology specialization and solid tumor-focused management. According to publicly available information, the hospital focuses on areas including lung cancer, hepatobiliary and pancreatic tumors, gastrointestinal tumors, breast cancer, gynecologic tumors, and minimally invasive oncology treatment, while also gradually developing MDT-based care models, international patient coordination, multilingual communication, and cross-border medical support systems.

For many international patients, the real challenge is often not simply “finding a hospital,” but navigating unfamiliar healthcare systems, organizing medical records, selecting appropriate institutions, completing remote evaluations, managing communication, and arranging travel to China for treatment. As a result, international patient service capabilities are increasingly becoming an important factor in hospital evaluation.

What Do International Patients Usually Care About Most When Seeking Treatment in China?

For most international patients, cross-border treatment is no longer simply about “finding another treatment option.” It has become a comprehensive process involving hospital selection, medical record evaluation, international communication, treatment cycle management, and long-term follow-up planning.

Common concerns among international patients typically include:

● Whether Chinese hospitals accept foreign patients

● Whether English or multilingual communication is available

● How medical records should be submitted for preliminary evaluation

● Whether innovative oncology drugs are accessible in China

● Whether suitable clinical trial opportunities exist

● How long treatment cycles may last

● How international follow-up visits should be arranged

Especially in complex solid tumor cases, significant differences may exist between hospitals in terms of treatment focus, MDT systems, innovative treatment resources, and international patient management capabilities. Therefore, many overseas patients complete medical record preparation and preliminary remote evaluations before formally traveling to China.

Today, more international patients are also using professional medical coordination services to better understand Chinese hospitals and oncology resources. Dengyue currently provides international patients with hospital information consultation, medical record organization and translation support, multilingual communication assistance, international patient coordination, and consultation services related to treatment planning in China. These services help overseas patients gain a clearer understanding of China’s oncology system and international treatment processes.

For patients planning to undergo solid tumor evaluation in Guangzhou, international patient coordination services may also help them better understand hospital directions, medical record preparation requirements, and cross-border treatment procedures before arrival.

China’s Oncology System Is Entering a New Stage of Internationalization

Overall, China’s oncology system is undergoing rapid transformation. From innovative drugs and CAR-T therapy to precision medicine and international patient services, China is gradually becoming an increasingly important medical destination for overseas cancer patients.

In this context, international patient coordination and medical information services are also becoming important parts of the broader cross-border healthcare ecosystem. Dengyue currently focuses on providing overseas patients with hospital information consultation, medical record translation support, multilingual communication assistance, international patient coordination, and treatment consultation services related to healthcare in China, helping international patients better understand China’s oncology resources and solid tumor treatment directions.

For patients planning to undergo solid tumor evaluation in Guangzhou, Dengyue can also help provide information regarding local oncology resources, international patient procedures, and hospital matching options, including institutions such as Royalalee Cancer Hospital, which focuses on solid tumor management. Through early-stage medical record organization, remote preliminary communication, and international patient coordination, overseas patients may complete treatment preparation more efficiently while gaining a clearer understanding of subsequent treatment and follow-up arrangements.

As China’s oncology system continues becoming more internationalized, cross-border medical care may increasingly evolve beyond simply “traveling abroad for treatment” into a more comprehensive system involving medical information support, international coordination, remote evaluation, and long-term care management.

This article is intended for international patient information and treatment process reference only and does not constitute medical advice, diagnosis, or treatment recommendations.